User: Guest

  



DOMAIN EXPERT ENGAGEMENTS

Number of executives repeatedly engaged by snail & email outreach*

POOL + OUTREACH

11069

Interactions with Platform & by Email *

INTERACTIONS

1328

Unique # Participated *

PARTICIPANTS

332

Responses Validated *

VALIDATIONS

36

* Platform engagements are dynamic. Stats are published quarterly.


  •  CODE

  •  PAGES

  •  DATE

  •  PRICE

    $

  •  DATA EXHIBITS

    125


TABLE OF CONTENTS


   Pages :    | $

   Study Reliability and Reporting Limitations.....I-1  
   Disclaimers.....I-2
Data Interpretation & Reporting Level.....I-2
  
   Quantitative Techniques & Analytics.....I-3
Product Definitions and Scope of Study.....I-3
  
   Bioanalytical Instruments.....I-4
Nuclear Magnetic Resonance.....I-4
Mass Spectroscopy.....I-4
Microplate Readers.....I-4
Chemotherapy Instruments.....I-4
High Throughput Screening (HTS).....I-4
Genomics.....I-4
Proteomics.....I-4
  
   Bioinformatics.....I-5
Biochip.....I-5
Pharmacogenomics.....I-5
Other Drug Discovery Technologies.....I-5
  
   Drug Discovery Outsourcing – A Necessity.....II-1
Current & Future Analysis.....II-1
Analysis by Geographic Region.....II-1
1$100
   Analysis by Technology Type.....II-2
1$100
   Bioinformatics.....II-3
Pharmacogenomics.....II-3
1$100
   Theragnostics.....II-41$100
   Targeted Therapy.....II-5
Mass Spectrometry – A New Catalyst for Technological Developments.....II-5
3$300
   New Technologies Fire Up Drug Discovery Market.....II-8
Obesity Related Diseases Driving Drug Discovery Research.....II-8
Biochips Change Face of Drug Discovery.....II-8
Genomics and Proteomics Gaining Prominence.....II-8
1$100
   Genomics Drives Bioinformatics Growth in Drug Discovery.....II-9
Market Scenario of Human Genome Sciences (HGS).....II-9
International Initiatives Expand Proteomics.....II-9
1$100
   Drug Discovery – Definition.....II-10
Drug Discovery Process.....II-10
1$100
   Drug Discovery Technologies.....II-11
Bioanalytical Instruments.....II-11
Nuclear Magnetic Resonance.....II-11
Mass Spectroscopy.....II-11
Microplate Readers.....II-11
1$100
   Chemotherapy Instruments.....II-12
High Throughput Screening.....II-12
Genomics.....II-12
Functional Genomics.....II-12
Structural Genomics.....II-12
Proteomics.....II-12
1$100
   Classification of Proteomics.....II-13
Bioinformatics.....II-13
Categories of Bioinformatics.....II-13
Advantages of Bioinformatics in Drug Discovery.....II-13
Market Highlights.....II-13
1$100
   Biochip.....II-14
Types of Biochips.....II-14
Pharmacogenomics.....II-14
1$100
   A Revolutionary Health Care Therapy.....II-151$100
   Other Drug Discovery Technologies.....II-16
Combinatorial Chemistry.....II-16
Lab-on-a-Chip.....II-16
1$100
   RNA Interference.....II-17
1$100
   Affymetrix Introduces Cytogenetic Solution.....II-18
Affymetrix Introduces DMET Early Access Solution.....II-18
Affymetrix Microarray Platform to feature in Pathwork’s Diagnostic Test.....II-18
Bio-Rad Laboratories Rolls Out Vasculitis Kit for BioPlex 2200 System.....II-18
1$100
   PerkinElmer Develops Products for High-Throughput Screening.....II-19
Tecan to Introduce Multimode Microplate Reader- Infinite M1000.....II-19
Waters Introduces Next-Generation MS System - Synapt™.....II-19
Tripos International Launches SYBYL®8.0.....II-19
1$100
   Bio-Rad Laboratories Unveils In2it A1C Analyzer for Diabetic Patients.....II-20
Charles River Launches Endosafe®-MCS™ Endotoxin Detection System.....II-20
Invitrogen Launches Human Embryonic Stem Cells Monitoring Kit.....II-20
1$100
   Sigma-Aldrich Introduces Proteomics Dynamic Range Standard.....II-21
Molecular Devices Develops Arcturus (XT) ™ LMC Instrument.....II-21
Fujitsu’s BioSciences Renames CAChe Software and Releases Scigress Explorer™.....II-21
Tripos International Unveils Topomer CoMFA®.....II-21
Tripos International Launches Topomer Search.....II-21
1$100
   Sigma-Aldrich Introduces GenomePlex®.....II-22
Agilent Unveils Dual Mode Microarray Platform.....II-22
Molecular Devices Launches ImageXpressULTRA™.....II-22
Applied Biosystems Commercializes TaqMan® Influenza.....II-22
Agilent Launches Assay Kits for Lab-On-a-Chip Platform.....II-22
1$100
   Affymetrix Unveils GeneChip® Microarrays.....II-23
Quantum Introduces Drug Discovery Software.....II-23
Invitrogen Launches Stealth™ RNAi Human Kinase Collection.....II-23
PerkinElmer Unveils BioXPRESSION™.....II-23
Affymetrix and ParAllele Jointly Introduce MegAllele™ Assays.....II-23
Agilent Launches HD-CGH Custom Microarrays.....II-23
1$100
   Applied Biosystems and MDS Sciex Unveil Tempo™ LC.....II-24
Beckman Coulter Presents Chemistry Analyzer for Clinical Testing.....II-24
Molecular Devices Launches ADME Assay Kits.....II-24
Applied Biosystems Unveils LS*LIMS™ Software.....II-24
Affymetrix Presents NimbleExpress™.....II-24
Agilent Releases Software for Pharma QC/QA.....II-24
1$100
   Affymetrix Acquires USB Corp.....II-25
Roche Acquires Ventana Medical Systems.....II-25
Bruker BioSciences Acquires Bruker BioSpin Group.....II-25
Takeda Signs Agreement to Take Over Millennium.....II-25
1$100
   Pfizer to Acquire Serenex.....II-26
Implant Sciences to Acquire Ion Metrics.....II-26
1$100
   NascaCell and Archemix Expand Partnership for Aptamer-Based Drugs.....II-27
DiscoveRx and Cosmo Bio Sign Distribution Agreement.....II-27
1$100
   Zydus Cadila Enters into Collaboration with Prolong Pharmaceuticals.....II-28
PsychoGenics Enters into Drug Discovery Agreement with Dainippon.....II-28
Zydus Cadila Collaborates with Karo Bio.....II-28
1$100
   Nicholas Piramal’s R&D Unit Extends Alliance with Eli Lilly.....II-29
Dr. Reddy’s Signs Collaboration Agreement with 7TM Pharma.....II-29
1$100
   Synamatix Enters into Collaboration with Universiti Malaysia.....II-30
Monogram Enters into Exclusive Collaboration Agreement with Avexa.....II-30
1$100
   Caliper Life Sciences Collaborates with Horizon Discovery.....II-31
Galapagos Signs Collaborative Agreement with Allergan for Drug Discovery.....II-31
Sigma-Aldrich Inks Exclusive Distribution Partnership with Atlas Antibodies.....II-31
1$100
   PsychoGenics Enters into New Agreement with Eli Lilly.....II-32
Ambrx and Eli Lilly Enter into Alliance for Drug Discovery.....II-32
BioSeek Enters into Agreement with Dainippon Sumitomo.....II-32
1$100
   NicOx Extends Collaboration with Pfizer.....II-33
BioFocus DPI Extends Contract with Lilly.....II-33
Invitrogen to Collaborate with Tecan.....II-33
1$100
   Ranbaxy Forms New Drug Discovery Company.....II-34
Protagen to Expand Protein Biochips Business.....II-34
Znomics Expands Facilities for Drug Discovery.....II-34
1$100
   Eli Lilly Acquires ICOS Corporation.....II-35
CMC Announces Acquisition of ICOS Biologics Facility from Eli Lilly.....II-35
SurModics Acquires Brookwood.....II-35
1$100
   Commonwealth Biotechnologies Acquires Tripos Discovery Research.....II-36
VASTox Acquires Dextra Laboratories and Daniolabs.....II-36
1$100
   Takeda Completes Acquisition of Paradigm.....II-37
Wyeth Completes the Acquisition of Haptogen.....II-37
1$100
   Roche Takes Over Nimblegen.....II-38
AMRI Acquires Pharmaceutical Manufacturing Units in India.....II-38
1$100
   Morvus Acquires Cardiff Biologicals and ProTides.....II-39
Agilent Technologies Acquires Stratagene.....II-39
1$100
   AstraZeneca Takes Over MedImmune.....II-40
Ocimum Acquires Gene Logic's Genomics Business.....II-40
Newsham Genetics Acquires Monsanto Choice Genetics.....II-40
Evotec Takes Over Combinature Biopharm’s Drug Discovery Unit.....II-40
1$100
   BioServe Takes Over Genomics Collaborative.....II-41
Thomson Takes Over Unleashed Informatics Ltd.....II-41
Thomson Completes Acquisition of Prous Science.....II-41
1$100
   MDS Acquires Molecular Devices.....II-42
Evotec to Take over Renovis.....II-42
Ecopia Merges with Caprion.....II-42
1$100
   Domainex Merges with NCE Discovery.....II-43
Thallion Sells Majority Interest in Caprion Proteomics Business.....II-43
Affymetrix Enters into Licensing Agreement with Empire Genomics.....II-43
1$100
   Graffinity Pharmaceuticals Signs Drug Discovery Agreement with Amgen.....II-44
ArQule Signs License Deal with Kyowa Hakko.....II-44
Toshiba, Canon and Others to Join Forces to Develop Biochips.....II-44
Orion and ChemDiv Enter into Collaborative Deal.....II-44
1$100
   Graffinity Enters into Drug Discovery Collaboration with Pfizer.....II-45
Tata Enterprise Establishes Pharmaceutical Development Centre.....II-45
Nicholas Piramal Collaborates with Merck.....II-45
1$100
   Eksigent Signs Distribution Agreement with Interface Engineering.....II-46
LEAD Therapeutics Enters Collaboration with Shang Pharma.....II-46
MDS Pharma Expands Chinese Lab Operations.....II-46
1$100
   Ambit Extends Drug Discovery Collaboration with Bristol - Myers Squibb.....II-47
PsychoGenics Enters into Agreement with Cephalon for Drug Discovery.....II-47
Abbott and Caprion Proteomics Extends Partnership.....II-47
1$100
   Agilent Technologies and BioNanomatrix Enters into Collaboration.....II-48
Evotec Extends Partnership with Boehringer Ingelheim.....II-48
Evotec and Interprotein Enter into Collaboration.....II-48
Galapagos Forms Drug Innovation Alliance with AstraZeneca.....II-48
1$100
   Proteome Systems and BD Enter into an Agreement.....II-49
Galapagos Extends Drug Innovation Partnership with Amgen.....II-49
1$100
   Dimerix Collaborates with NCDS.....II-50
ACE BioSciences and CLC Bio Enter into Collaborative Agreement.....II-50
1$100
   Ambrx Enters into Strategic Agreement with Merck & Co.....II-51
Galapagos and Cystic Fibrosis Collaborate for Drug Discovery.....II-51
1$100
   BioDiscovery Collaborates with Illumina.....II-52
Advinus Collaborates with DNDi.....II-52
1$100
   Jubilant & Forest Enter into Partnership Deal.....II-53
Cisbio to Employ Lumi4™ Technology of Lumiphore.....II-53
Invitrogen Corporation Signs Agreement with Emiliem to Screen Kinase
  Inhibitors.....II-53
1$100
   AMRI Establishes New Center in India.....II-54
Actavis Takes Over Abrika.....II-54
Galapagos Announces Acquisition of Inpharmatica.....II-54
PerkinElmer Acquires Proteomics Technology from Agilix.....II-54
1$100
   BD Finishes Acquisition of GeneOhm.....II-55
Albany Acquires ComGenex in Hungary.....II-55
Agilent Acquires Yokogawa.....II-55
1$100
   Strand Forms Partnership with Microsoft BioIT Alliance.....II-56
Nicholas Piramal Signs License Agreement with Morvus Technology.....II-56
Cellomics and Evotec Sign a Patent License Agreement.....II-56
PerkinElmer Opens New Technology Center in Shanghai.....II-56
1$100
   Affymetrix Acquires ParAllele.....II-57
Agilent Acquires Computational Biology.....II-57
MultiCell and Living Cell Enter into a Joint Venture.....II-57
1$100
   Fujitsu and Ensemble Enter into Licensing Agreement.....II-58
Structural GenomiX Modifies Licensing Agreement with Lilly.....II-58
Provid Enters into Research Services Agreement with Palatin.....II-58
NascaCell Signs Co-marketing Agreement with DPI.....II-58
Evotec and P&G Sign Supply Agreement.....II-58
Invitrogen Signs Collaborative Agreement with NCDS.....II-58
1$100
   HistoRx Enters into Collaboration with Eli Lilly.....II-59
Invitrogen and Applied Biosystems Forge Strategic Alliance.....II-59
UCB and ChemBridge Form Collaboration in Discovery Chemistry.....II-59
Pharmacopeia and CV Therapeutics Form Drug Discovery and Development
  Collaboration.....II-59
1$100
   OriGene Enters into Collaboration with Cytomyx.....II-60
Discovery Partners Divests Discovery Systems Business to Nexus.....II-60
CRL Acquires River Valley Farms.....II-60
Agilent Acquires Silicon.....II-60
Medarex Acquires Ability Biomedical.....II-60
1$100
   National Instruments Enters into Joint Venture Agreement with Agilent.....II-61
Amersham Enters into 3-Year Distribution Agreement with Guava.....II-61
ChemBridge Signs an Agreement with Merck & Co......II-61
Bristol-Myers Collaborates with MEDX.....II-61
Bayer Enters into Partnership with Physiomics.....II-61
Pharmacopeia Spins-Off Pharmacopeia Drug Discovery.....II-61
1$100
   Abbott Enters into Collaboration with Caprion.....II-62
Vertex Divests Instrumentation Assets to Aurora.....II-62
1$100
   Abbott Laboratories (US).....II-63
Affymetrix Inc. (US).....II-63
Agilent Technologies Inc. (US).....II-63
Albany Molecular Research, Inc. (US).....II-63
1$100
   Amersham Biosciences (US).....II-64
Applera Corporation (US).....II-64
ArQule Inc. (US).....II-64
AstraZeneca (UK).....II-64
1$100
   BD Biosciences (US).....II-65
Bio-Rad Laboratories, Inc. (US).....II-65
BioSciences Group (Japan).....II-65
Caliper Life Sciences, Inc. (US).....II-65
1$100
   Capital GenomiX (US).....II-66
Caprion Proteomics (Canada).....II-66
Charles River Laboratories International, Inc. (US).....II-66
ChemBridge Corporation (US).....II-66
deCODE Genetics, Inc (Iceland).....II-66
1$100
   Evotec AG (Germany).....II-67
Galapagos NV (Belgium).....II-67
Incyte Corporation (Formerly Incyte Genomics Inc.) (US).....II-67
Infinity Pharmaceuticals, Inc. (US).....II-67
Invitrogen Corporation (US).....II-67
1$100
   Medarex, Inc. (US).....II-68
Merck & Co., Inc. (US).....II-68
Millennium Pharmaceuticals, Inc. (US).....II-68
National Center for Drug Screening (China).....II-68
PerkinElmer, Inc. (US).....II-68
Pharmacopeia Inc. (US).....II-68
1$100
   Proteome Systems (Australia).....II-69
Quantum Pharmaceuticals (Russia).....II-69
Shimadzu Corporation (Japan).....II-69
Sigma-Aldrich (US).....II-69
Tecan Group (Switzerland).....II-69
1$100
   Thallion Pharmaceuticals, Inc. (Canada).....II-70
Tripos International (US).....II-70
1$100
   Table 1: World Recent Past, Current & Future Analysis for Drug Discovery Technologies by Geographic Region – US, Canada, Japan, Europe and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2001 through 2010 (includes corresponding Graph/Chart).....II-711$300
   Table 2: World Long-term Projections for Drug Discovery Technologies by Geographic Region – US, Canada, Japan, Europe and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....II-721$300
   Table 3: World 10-Year Perspective for Drug Discovery Technologies by Geographic Region - Percentage Breakdown of Value Sales for US, Canada, Japan, Europe and Rest of World Markets for Years 2003, 2008 & 2012 (includes corresponding Graph/Chart).....II-731$300
   Analytics by Drug Discovery Technology Type.....II-74
Table 4: World Recent Past, Current & Future Analysis for Bioanalytical Instruments by Geographic Region – US, Canada, Japan, Europe and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2001 through 2010 (includes corresponding Graph/Chart).....II-74
1$300
   Table 5: World Long-term Projections for Bioanalytical Instruments by Geographic Region – US, Canada, Japan, Europe and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....II-751$300
   Table 6: World 10-Year Perspective for Bioanalytical Instruments by Geographic Region - Percentage Breakdown of Value Sales for US, Canada, Japan, Europe and Rest of World Markets for Years 2003, 2008 & 2012 (includes corresponding Graph/Chart).....II-761$300
   Table 7: World Recent Past, Current & Future Analysis for High Throughput Screening (HTS) by Geographic Region – US, Canada, Japan, Europe and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2001 through 2010 (includes corresponding Graph/Chart).....II-771$300
   Table 8: World Long-term Projections for High Throughput Screening (HTS) by Geographic Region – US, Canada, Japan, Europe and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....II-781$300
   Table 9: World 10-Year Perspective for High Throughput Screening (HTS) by Geographic Region - Percentage Breakdown of Value Sales for US, Canada, Japan, Europe and Rest of World Markets for Years 2003, 2008 & 2012 (includes corresponding Graph/Chart).....II-791$300
   Table 10: World Recent Past, Current & Future Analysis for Biochip by Geographic Region – US, Canada, Japan, Europe and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2001 through 2010 (includes corresponding Graph/Chart).....II-801$300
   Table 11: World Long-term Projections for Biochip by Geographic Region – US, Canada, Japan, Europe and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....II-811$300
   Table 12: World 10-Year Perspective for Biochip by Geographic Region - Percentage Breakdown of Value Sales for US, Canada, Japan, Europe and Rest of World Markets for Years 2003, 2008 & 2012 (includes corresponding Graph/Chart).....II-821$300
   Table 13: World Recent Past, Current & Future Analysis for Proteomics by Geographic Region – US, Canada, Japan, Europe and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2001 through 2010 (includes corresponding Graph/Chart).....II-831$300
   Table 14: World Long-term Projections for Proteomics by Geographic Region – US, Canada, Japan, Europe and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....II-841$300
   Table 15: World 10-Year Perspective for Proteomics by Geographic Region - Percentage Breakdown of Value Sales for US, Canada, Japan, Europe and Rest of World Markets for Years 2003, 2008 & 2012 (includes corresponding Graph/Chart).....II-851$300
   Table 16: World Recent Past, Current & Future Analysis for Genomics by Geographic Region – US, Canada, Japan, Europe and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2001 through 2010 (includes corresponding Graph/Chart).....II-861$300
   Table 17: World Long-term Projections for Genomics by Geographic Region – US, Canada, Japan, Europe and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....II-871$300
   Table 18: World 10-Year Perspective for Genomics by Geographic Region - Percentage Breakdown of Value Sales for US, Canada, Japan, Europe and Rest of World Markets for Years 2003, 2008 & 2012 (includes corresponding Graph/Chart).....II-881$300
   Table 19: World Recent Past, Current & Future Analysis for Bioinformatics by Geographic Region – US, Canada, Japan, Europe and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2001 through 2010 (includes corresponding Graph/Chart).....II-891$300
   Table 20: World Long-term Projections for Bioinformatics by Geographic Region – US, Canada, Japan, Europe and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....II-901$300
   Table 21: World 10-Year Perspective for Bioinformatics by Geographic Region - Percentage Breakdown of Value Sales for US, Canada, Japan, Europe and Rest of World Markets for Years 2003, 2008 & 2012 (includes corresponding Graph/Chart).....II-911$300
   Table 22: World Recent Past, Current & Future Analysis for Pharmacogenomics by Geographic Region – US, Canada, Japan, Europe and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2001 through 2010 (includes corresponding Graph/Chart).....II-921$300
   Table 23: World Long-term Projections for Pharmacogenomics by Geographic Region – US, Canada, Japan, Europe and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....II-931$300
   Table 24: World 10-Year Perspective for Pharmacogenomics by Geographic Region - Percentage Breakdown of Value Sales for US, Canada, Japan, Europe and Rest of World Markets for Years 2003, 2008 & 2012 (includes corresponding Graph/Chart).....II-941$300
   Table 25: World Recent Past, Current & Future Analysis for Other Drug Discovery Technologies by Geographic Region – US, Canada, Japan, Europe and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2001 through 2010 (includes corresponding Graph/Chart).....II-951$300
   Table 26: World Long-term Projections for Other Drug Discovery Technologies by Geographic Region – US, Canada, Japan, Europe and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....II-961$300
   Table 27: World 10-Year Perspective for Other Drug Discovery Technologies by Geographic Region - Percentage Breakdown of Value Sales for US, Canada, Japan, Europe and Rest of World Markets for Years 2003, 2008 & 2012 (includes corresponding Graph/Chart).....II-971$300
   A. Market Analysis.....III-1
Overview.....III-1
US Leads the World High Throughput Screening (HTS) Market.....III-1
1$75
   Current & Future Analysis.....III-2
Product Launches.....III-2
7$525
   Strategic Corporate Developments.....III-919$875
   Focus on Select US Players.....III-28
Abbott Laboratories.....III-28
Affymetrix Inc......III-28
Agilent Technologies Inc......III-28
Albany Molecular Research, Inc......III-28
1$75
   Amersham Biosciences.....III-29
Applera Corporation.....III-29
ArQule Inc......III-29
1$75
   BD Biosciences.....III-30
Bio-Rad Laboratories, Inc......III-30
Caliper Life Sciences, Inc......III-30
Capital GenomiX.....III-30
1$75
   Charles River Laboratories International, Inc......III-31
ChemBridge Corporation.....III-31
deCODE Genetics, Inc......III-31
HistoRx, Inc......III-31
Incyte Corporation (Formerly Incyte Genomics Inc.).....III-31
1$75
   Infinity Pharmaceuticals, Inc......III-32
Invitrogen Corporation.....III-32
Medarex, Inc......III-32
Merck & Co., Inc......III-32
Millennium Pharmaceuticals, Inc......III-32
PerkinElmer, Inc......III-32
1$75
   Pharmacopeia Inc......III-33
Provid Pharmaceuticals, Inc......III-33
Tigris Pharmaceuticals, Inc......III-33
Sigma-Aldrich.....III-33
Tripos International.....III-33
1$75
   B. Market Analytics.....III-34
Table 28: US Recent Past, Current & Future Analysis for Drug Discovery Technologies by Technology Type – Bioanalytical Instruments, HTS, Biochip, Proteomics, Genomics, Bioinformatics, Pharmacogenomics and Other Markets Independently Analyzed with Annual Sales in US$ Million for Years 2001 through 2010 (includes corresponding Graph/Chart).....III-34
1$150
   Table 29: US Long-term Projections for Drug Discovery Technologies by Technology Type – Bioanalytical Instruments, High Throughput Screening (HTS), Biochip, Proteomics, Genomics, Bioinformatics, Pharmacogenomics and Other Markets Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-351$150
   Table 30: US 10-Year Perspective for Drug Discovery Technologies by Technology Type - Percentage Breakdown of Value Sales for Bioanalytical Instruments, HTS, Biochip, Proteomics, Genomics, Bioinformatics, Pharmacogenomics and Other Markets for Years 2003, 2008 & 2012 (includes corresponding Graph/Chart).....III-36
1$150
   A. Market Analysis.....III-37
Current & Future Analysis.....III-37
Strategic Corporate Developments.....III-37
1$75
   Focus on Select Canadian Players.....III-38
Caprion Proteomics.....III-38
Thallion Pharmaceuticals, Inc......III-38
1$75
   B. Market Analytics.....III-39
Table 31: Canadian Recent Past, Current & Future Analysis for Drug Discovery Technologies by Technology Type – Bioanalytical Instruments, High Throughput Screening (HTS), Biochip, Proteomics, Genomics, Bioinformatics, Pharmacogenomics and Other Markets Independently Analyzed with Annual Sales in US$ Million for Years 2001 through 2010 (includes corresponding Graph/Chart).....III-39
1$150
   Table 32: Canadian Long-term Projections for Drug Discovery Technologies by Technology Type – Bioanalytical Instruments, High Throughput Screening (HTS), Biochip, Proteomics, Genomics, Bioinformatics, Pharmacogenomics and Other Markets Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-401$150
   Table 33: Canadian 10-Year Perspective for Drug Discovery Technologies by Technology Type - Percentage Breakdown of Value Sales for Bioanalytical Instruments, High Throughput Screening (HTS), Biochip, Proteomics, Genomics, Bioinformatics, Pharmacogenomics and Other Markets for Years 2003, 2008 & 2012 (includes corresponding Graph/Chart).....III-41
1$150
   A. Market Analysis.....III-42
Current & Future Analysis.....III-42
Japan Resembles US in Life Science Research.....III-42
Strategic Corporate Developments.....III-42
1$75
   Focus on Select Japanese Players.....III-43
BioSciences Group.....III-43
Shimadzu Corporation.....III-43
1$75
   B. Market Analytics.....III-44
Table 34: Japanese Recent Past, Current & Future Analysis for Drug Discovery Technologies by Technology Type – Bioanalytical Instruments, High Throughput Screening (HTS), Biochip, Proteomics, Genomics, Bioinformatics, Pharmacogenomics and Other Markets Independently Analyzed with Annual Sales in US$ Million for Years 2001 through 2010 (includes corresponding Graph/Chart).....III-44
1$150
   Table 35: Japanese Long-term Projections for Drug Discovery Technologies by Technology Type – Bioanalytical Instruments, High Throughput Screening (HTS), Biochip, Proteomics, Genomics, Bioinformatics, Pharmacogenomics and Other Markets Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-451$150
   Table 36: Japanese 10-Year Perspective for Drug Discovery Technologies by Technology Type - Percentage Breakdown of Value Sales for Bioanalytical Instruments, High Throughput Screening (HTS), Biochip, Proteomics, Genomics, Bioinformatics, Pharmacogenomics and Other Markets for Years 2003, 2008 & 2012 (includes corresponding Graph/Chart).....III-46
1$150
   A. Market Analysis.....III-47
Current & Future Analysis.....III-47
An Overview of Pharmacogenomics and Personalized Medicine.....III-47
1$75
   Emerging Trends in Proteomics Technology.....III-48
Protein Classification.....III-48
1$75
   Protein Separation.....III-491$75
   Market Trends.....III-50
European Market for Drug Discovery Tools.....III-50
UK Government Supports Proteomics Research.....III-50
Drug Discovery Outsourcing in Europe.....III-50
1$75
   Recent Industry Activity.....III-519$675
   Focus on Select European Players.....III-60
AstraZeneca (UK).....III-60
deCODE Genetics, Inc (Iceland).....III-60
Evotec AG (Germany).....III-60
NascaCell IP GmbH (Germany).....III-60
1$75
   Quantum Pharmaceuticals (Russia).....III-61
Tecan Group (Switzerland).....III-61
UCB (Belgium).....III-61
1$75
   B. Market Analytics.....III-62
Table 37: European Recent Past, Current & Future Analysis for Drug Discovery Technologies by Technology Type – Bioanalytical Instruments, High Throughput Screening (HTS), Biochip, Proteomics, Genomics, Bioinformatics, Pharmacogenomics and Other Markets Independently Analyzed with Annual Sales in US$ Million for Years 2001 through 2010 (includes corresponding Graph/Chart).....III-62
1$150
   Table 38: European Long-term Projections for Drug Discovery Technologies by Technology Type – Bioanalytical Instruments, High Throughput Screening (HTS), Biochip, Proteomics, Genomics, Bioinformatics, Pharmacogenomics and Other Markets Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-631$150
   Table 39: European 10-Year Perspective for Drug Discovery Technologies by Technology Type - Percentage Breakdown of Value Sales for Bioanalytical Instruments, High Throughput Screening (HTS), Biochip, Proteomics, Genomics, Bioinformatics, Pharmacogenomics and Other Markets for Years 2003, 2008 & 2012 (includes corresponding Graph/Chart).....III-64
1$150
   A. Market Analysis.....III-65
Current & Future Analysis.....III-65
Asia-Pacific.....III-65
Emerging Opportunities.....III-65
Cost Advantage in Asia Attracts Global Drug Discovery Industry.....III-65
Regulations Affect Asia-Pacific Drug Discovery Market.....III-65
1$75
   India.....III-66
Bioinformatics Market in India.....III-66
Scope and Demand for Bioinformatics Market to Expand Significantly by
  2010.....III-66
1$75
   Discovery of Therapeutic Molecules – A New Buzzword for Growth
  Acceleration.....III-67
1$75
   Strategic Corporate Developments.....III-687$525
   Focus on Select Players.....III-75
National Center for Drug Screening (China).....III-75
Proteome Systems (Australia).....III-75
1$75
   B. Market Analytics.....III-76
Table 40: Rest of World Recent Past, Current & Future Analysis for Drug Discovery Technologies by Technology Type – Bioanalytical Instruments, High Throughput Screening (HTS), Biochip, Proteomics, Genomics, Bioinformatics, Pharmacogenomics & Other Markets Independently Analyzed with Annual Sales in US$ Million for Years 2001 through 2010 (includes corresponding Graph/Chart).....III-76
1$150
   Table 41: Rest of World Long-term Projections for Drug Discovery Technologies by Technology Type – Bioanalytical Instruments, High Throughput Screening (HTS), Biochip, Proteomics, Genomics, Bioinformatics, Pharmacogenomics and Other Markets Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-771$150
   Table 42: Rest of World 10-Year Perspective for Drug Discovery Technologies by Technology Type - Percentage Breakdown of Value Sales for Bioanalytical Instruments, High Throughput Screening (HTS), Biochip, Proteomics, Genomics, Bioinformatics, Pharmacogenomics and Other Markets for Years 2003, 2008 & 2012 (includes corresponding Graph/Chart).....III-781$150